---
document_datetime: 2025-09-19 15:44:59
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tepkinly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tepkinly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.0237142
conversion_datetime: 2025-12-26 19:56:13.097215
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tepkinly

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 09/09/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291328   |
|---------------------|

<div style=\"page-break-after: always\"></div>

| Renewal - 1 year / EMA/R/0000257200   | - Renewal - Accepted Renewal of marketing authorisation.   | 22/05/2025   | 17/07/2025   | SmPC and PL   | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Tepkinly, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion.   |
|---------------------------------------|------------------------------------------------------------|--------------|--------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|